Faster Cardiac Answers with High‑Sensitivity Troponin

Rhea-AI Summary

QuidelOrtho (Nasdaq: QDEL) released episode 56 of its Science Bytes podcast on Feb 19, 2026, featuring Dr. Lindy Carlstrom, Global Medical Affairs Manager for Acute Care.

The episode explains how high‑sensitivity troponin (hs troponin) enables earlier detection of cardiac injury, tighter reproducibility at low levels, shorter serial testing protocols (0/1 or 0/2 hour), sex‑specific cutoffs, and emerging applications in cardio‑oncology, perioperative care, and long‑term risk prediction.

Key Figures

Podcast episode: 56 Serial testing intervals: 0/1- or 0/2-hour

2 metrics

Podcast episode 56 Episode number of Science Bytes discussing high-sensitivity troponin

Serial testing intervals 0/1- or 0/2-hour Protocols for accelerated cardiac rule-out pathways

Market Reality Check

Price: $24.16 Vol: Volume 1,080,580 is below...

normal vol

$24.16 Last Close

Volume Volume 1,080,580 is below the 20-day average of 1,344,366. normal

Technical Trading below 200-day MA of 28.23, despite a recent 4.45% daily gain.

Peers on Argus

Momentum scanner shows only one peer, ITGR, up 12.77% with no news. Core peers l...

1 Up

Momentum scanner shows only one peer, ITGR, up 12.77% with no news. Core peers like PRCT and ATEC are down while INSP, HAE, and LIVN are modestly up, suggesting QDEL’s move is more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Feb 18 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 18	Conference appearance	Neutral	+4.5%	Announcement of presentation at Raymond James institutional investor conference.
Feb 11	Earnings results	Neutral	-1.4%	Reported FY25 results with impairment-driven GAAP loss and 2026 guidance.
Feb 03	Awards recognition	Positive	+1.2%	Received Excellence Services Label in EMEA and two Stevie Awards.
Jan 22	Podcast release	Positive	+3.9%	Released Science Bytes episode on blood supply challenges and transfusion medicine.
Jan 21	Earnings date set	Neutral	-10.1%	Scheduled Q4 and FY25 results release and related conference call logistics.

Pattern Detected

Recent non-financial news such as podcasts and awards often coincided with positive price moves, while neutral scheduling or leadership/earnings items sometimes saw negative reactions.

Recent Company History

Over recent months, QuidelOrtho has mixed operational and investor-facing news. The company reported FY25 revenue of $2.73B, adjusted EBITDA of $597M with a 22% margin, but also a $701M goodwill impairment leading to a GAAP net loss of $1.13B. Guidance for 2026 called for $2.7–$2.9B revenue and adjusted EPS of $2.00–$2.42. Alongside this, QDEL announced an earnings date, corporate awards, and multiple Science Bytes podcast episodes. These educational and branding updates, including today’s cardiac-diagnostics episode, fit a pattern of frequent communication around its diagnostics portfolio.

Market Pulse Summary

This announcement highlights QuidelOrtho’s focus on high-sensitivity troponin and accelerated cardia...

Analysis

This announcement highlights QuidelOrtho’s focus on high-sensitivity troponin and accelerated cardiac pathways, emphasizing faster rule-out protocols like 0/1‑ or 0/2‑hour testing. It extends a recent pattern of Science Bytes episodes that spotlight different parts of the diagnostics portfolio. In the background, investors must also track FY25 results with $2.73B revenue, a $701M impairment-driven GAAP loss, and 2026 guidance, plus recent regulatory filings and insider transactions for a fuller risk–reward picture.

Key Terms

high-sensitivity troponin, hs troponin, myocardial injury, cardio-oncology

4 terms

high-sensitivity troponin medical

"discuss how high-sensitivity troponin (hs troponin) is transforming early cardiac diagnosis"

A high-sensitivity troponin test measures very small amounts of a protein released into the blood when heart muscle is injured. Acting like a sensitive smoke alarm for the heart, it helps doctors detect heart attacks earlier, estimate a patient’s short-term risk, and guide treatment decisions; for investors, shifts in test use, accuracy, or regulation can influence makers of diagnostic tests, hospital spending, and related medical markets.

hs troponin medical

"high-sensitivity troponin (hs troponin) is transforming early cardiac diagnosis"

High-sensitivity troponin is a blood test that detects tiny amounts of a heart muscle protein released when the heart is damaged; think of it as a very sensitive smoke detector for heart injury. It matters to investors because adoption, regulatory approval, and changes in how widely the test is used affect demand for diagnostic devices, lab services and emergency-care protocols, which in turn influence revenue and cost patterns across healthcare companies.

myocardial injury medical

"helps clinicians distinguish true myocardial injury from analytical noise"

Myocardial injury is damage to the heart muscle that shows up on medical tests such as blood markers or imaging and can result from reduced blood flow, infection, toxins, or physical stress. It matters to investors because it can change clinical trial results, trigger regulatory scrutiny or liability, affect product safety perceptions, and influence workforce health and insurance costs—similar to a critical part of a machine failing and changing future performance and expense.

cardio-oncology medical

"Emerging research is exploring new applications in cardio‑oncology, perioperative care"

A medical specialty that focuses on preventing, detecting and managing heart problems caused by cancer and its treatments. Like adding safety checks to an engine after installing a new part, cardio-oncology helps identify and reduce heart damage from chemotherapy, radiation or targeted drugs, which matters to investors because cardiovascular risks can affect a therapy’s approval, usage, long-term costs, liability and overall market value.

AI-generated analysis. Not financial advice.

SAN DIEGO, Feb. 19, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 56 of its Science Bytes podcast, featuring Dr. Lindy Carlstrom, Global Medical Affairs Manager for Acute Care. In this episode, Carlstrom and host Josh Casey discuss how high-sensitivity troponin (hs troponin) is transforming early cardiac diagnosis and improving emergency department efficiency.

Key Insights

• Faster answers when time matters: hs troponin detects cardiac injury earlier than traditional assays, enabling quicker diagnosis and reducing time spent in the emergency department
• Precision that clinicians can trust: With tight reproducibility at low troponin levels, hs troponin helps clinicians distinguish true myocardial injury from analytical noise
• Safer, accelerated pathways: Shortened serial testing intervals (0/1‑ or 0/2‑hour protocols) support rapid rule‑out of heart attacks and speed up patient flow
• More equitable care: Sex‑specific cutoffs and higher accuracy help ensure more consistent diagnosis across diverse patient groups
• Broader potential ahead: Emerging research is exploring new applications in cardio‑oncology, perioperative care and long‑term risk prediction

Episode 56 highlights how combining precision diagnostics with clinical context supports faster, more confident decisions, and ultimately better outcomes for patients with suspected cardiac events.

Listen to the QuidelOrtho Science Bytes podcast on major streaming platforms or at: https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.

About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com

Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
Media@QuidelOrtho.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/faster-cardiac-answers-with-highsensitivity-troponin-302692081.html

SOURCE QuidelOrtho Corporation

FAQ

How does high‑sensitivity troponin improve emergency department workflow for QDEL?

Hs troponin enables faster rule‑out and quicker decisions in the ED, reducing patient time. According to QuidelOrtho, earlier detection and shortened serial testing (0/1 or 0/2 hour) support rapid rule‑out of heart attacks and speed patient flow.

What clinical advantages of hs troponin did QuidelOrtho (QDEL) highlight in the podcast?

The podcast highlights earlier detection, tight reproducibility, and sex‑specific cutoffs for more accurate diagnosis. According to QuidelOrtho, these features help distinguish true myocardial injury from analytical noise and support equitable diagnosis across groups.

Does QuidelOrtho mention specific serial testing protocols for hs troponin (QDEL)?

Yes, the episode references shortened serial testing protocols such as 0/1‑hour and 0/2‑hour algorithms. According to QuidelOrtho, these accelerated protocols facilitate rapid rule‑out of myocardial infarction and improve emergency department efficiency.

What future applications for hs troponin did QuidelOrtho discuss on the podcast (QDEL)?

QuidelOrtho discussed emerging uses in cardio‑oncology, perioperative care, and long‑term risk prediction. According to QuidelOrtho, ongoing research is exploring these broader clinical roles beyond acute cardiac diagnosis.

Where can investors or clinicians listen to QuidelOrtho Science Bytes episode 56 (QDEL)?

Episode 56 is available on major streaming platforms and the company website. According to QuidelOrtho, listeners can access the episode via podcast services or at the QuidelOrtho resources and podcasts page.

How does hs troponin support more equitable cardiac diagnosis according to QuidelOrtho (QDEL)?

Hs troponin uses sex‑specific cutoffs and higher accuracy to reduce diagnostic disparities. According to QuidelOrtho, these attributes help ensure more consistent detection of myocardial injury across diverse patient groups.